Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Size to Reach USD 64.09 Billion by 2033 | Growing at a 35.3% CAGR Driven by Precision Medicine, RNAi Therapies, and Early Disease Diagnosis

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing at a CAGR of 35.3% during the forecast period from 2026 to 2033. The market is witnessing exceptional growth driven by increasing awareness of rare cardiac diseases, improved diagnostic capabilities, and the rapid development of disease-modifying therapies. ATTR-CM, once considered an underdiagnosed condition, is now receiving significant clinical attention due to advancements in genetic testing, non-invasive imaging, and biomarker-based diagnosis. Growing adoption of precision medicine and rising investments in rare disease research are further accelerating market expansion.